FrancophonIA/ELRC3.0 huggingface dataset:
English: • you have severe heart failure or severe uncontrolled heart disease and have rheumatoid arthritis,
Slovenian: • imate hudo srčno popuščanje ali hudo, neurejeno srčno bolezen in imate tudi revmatoidni artritis, granulomatozo s poliangiitisom, mikroskopski poliangiitis ali navadni pemfigus.
English: Only the highest frequency observed in the trials is reported 1 includes reactivation and primary infections; frequency based on R-FC regimen in relapsed/refractory CLL 2 see also section infection below
Slovenian: 1 Vključuje reaktivacijo in primarne okužbe; pogostnost temelji na režimu R-FC pri bolnikih s KLL, pri katerih se je bolezen ponovila, ali pri neodzivnih bolnikih.
English: Serum ickness-like reaction
Slovenian: reakcija, podobna serumski bolezni
English: The antibody is produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity chromatography and ion exchange, including specific viral inactivation and removal procedures.
Slovenian: in očiščeno z afinitetno kromatografijo ter ionsko izmenjavo, vključno s specifičnimi postopki inaktivacije in odstranjevanja virusov.
English: Lung infiltration
Slovenian: infiltracija pljuč
English: Infusion-related reactions in the pemphigus vulgaris clinical study were common (58%).
Slovenian: V klinični študiji pri navadnem pemfigusu so bile z infundiranjem povezane reakcije pogoste (58 %).
English: What Rixathon is and what it is used for What Rixathon is
Slovenian: Kaj je zdravilo Rixathon in za kaj ga uporabljamo
English: Overall survival
Slovenian: Celokupno preživetje (OS)
English: Table 15 Summary of efficacy by baseline autoantibody status Week 24
Slovenian: Povzetek učinkovitosti glede na izhodiščno stanje protiteles
English: The recommended dose of Rixathon in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.
Slovenian: Priporočeni odmerek zdravila Rixathon v kombinaciji s kemoterapijo za indukcijsko zdravljenje bolnikov s folikularnimi limfomi, ki se predhodno še niso zdravili ali se na prejšnje zdravljenje niso odzvali ali se jim je bolezen ponovila, je: 375 mg/m2 telesne površine na cikel do 8 ciklov.
English: c) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis
Slovenian: c) Če se zdravite zaradi granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa
English: A maintenance infusion of 500 mg IV should be administered at months 12 and 18, and then every 6 months thereafter if needed, based on clinical evaluation.
Slovenian: Vzdrževalno infuzijo 500 mg intravensko je treba uporabiti v 12. in 18. mesecu in nato vsakih
English: Table 11 Treatment of relapsed/refractory chronic lymphocytic leukaemia - overview of efficacy results for rituximab plus FC vs. FC alone (25.3 months median observation time)
Slovenian: Zdravljenje kronične limfocitne levkemije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje - pregled rezultatov o učinkovitosti za rituksimab v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC (mediana opazovanja 25,3 meseca)
English: A total of 23/99 (23%) rituximab-treated patients from the induction of remission trial tested positive for ADA by 18 months.
Slovenian: Do 18. meseca je imelo pozitiven izvid ADA skupno 23 od 99 (23 %) bolnikov, ki so bili v preskušanju zdravljeni z rituksimabom za indukcijo remisije.
English: Mean Cmax for serum rituximab following first infusion ranged from 157 to 171 μg/mL for 2 x 500 mg dose and ranged from 298 to 341 μg/mL for 2 x 1,000 mg dose.
Slovenian: Povprečna serumska Cmax rituksimaba po prvi infuziji je bila 157 do 171 μg/ml za 2 x 500 mg odmerek ter 298 do 341 μg/ml za
English: The recommended dosage of Rixathon in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total.
Slovenian: Priporočeni odmerek zdravila Rixathon v kombinaciji s kemoterapijo pri bolnikih, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila, je 375 mg/m2 telesne površine, ki ga damo na dan 0 prvega cikla zdravljenja, v naslednjih ciklih zdravljenja pa dajemo 1. dan 500 mg/m2 telesne površine, skupaj 6 ciklov.
English: Do not breast-feed while you are being treated with Rixathon.
Slovenian: Med zdravljenjem z zdravilom Rixathon ne smete dojiti.
English: Rixathon in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.
Slovenian: Zdravilo Rixathon je v kombinaciji z metotreksatom indicirano za zdravljenje odraslih bolnikov z zelo aktivnim revmatoidnim artritisom, ki niso zadostno odgovorili na druga imunomodulirajoča zdravila
English: Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Slovenian: Rituksimab v kombinaciji z metotreksatom zmanjša hitrost napredovanja okvar sklepov, ki jih spremljamo z rentgenskim slikanjem, in izboljša funkcijsko zmogljivost.
English: Angina pectoris, atrial fibrillation, heart failure, myocardial infarction
Slovenian: Srčne bolezni angina pektoris, atrijska fibrilacija,
English: There were no CTC Grade 4 IRRs and no deaths due to IRRs in the clinical trials.
Slovenian: Reakcij stopnje 4 po lestvici skupnih kriterijev toksičnosti (CTC, Common Toxicity Criteria) in smrti zaradi reakcij v kliničnih preskušanjih ni bilo.
English: • feeling tired or dizzy
Slovenian: • občutek utrujenosti ali omotičnosti,
English: Arthralgia / musculoskeletal pain, osteoarthritis, bursitis
Slovenian: osteoartroza, burzitis
English: Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia.
Slovenian: Zdravilo Rixathon je v kombinaciji s kemoterapijo indicirano za zdravljenje bolnikov s kronično limfocitno levkemijo, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila.
English: A total of 197 patients aged 15 years or older with severely, active granulomatosis with polyangiitis (75%) and microscopic polyangiitis (24%) were enrolled and treated in an active-comparator, randomised, double-blind, multicenter, non-inferiority trial.
Slovenian: V randomiziranem, dvojno slepem, s placebom kontroliranem multicentričnem preskušanju neinferiornosti z aktivnim primerjalnim zdravilom so vključili in v njej zdravili skupno 197 bolnikov, starih 15 let ali več s hudo, aktivno granulomatozo s poliangiitisom (75 %) in mikroskopskim poliangiitisom (24 %).
English: In the maintenance therapy clinical trial, 30/57 (53%) patients in the rituximab arm experienced infections.
Slovenian: V kliničnem preskušanju vzdrževalnega zdravljenja so se okužbe v skupini z rituksimabom pojavile pri 30 od 57 (53 %) bolnikov.
English: Subsequent doses of Rixathon can be infused at an initial rate of 100 mg/h, and increased by 100 mg/h increments at 30 minute intervals, to a maximum of 400 mg/h.
Slovenian: Nadaljnje odmerke zdravila Rixathon lahko dajemo z začetno hitrostjo 100 mg/h, ki jo lahko vsakih
English: d) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis
Slovenian: d) Če se zdravite zaradi granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa
English: Minor relapses (not life threatening and not involving major organ damage) occurred in seven patients in the rituximab group (12%) and eight patients in the azathioprine group (14%).
Slovenian: Blažji recidivi (takšni, ki niso bili življenjsko ogrožajoči in niso vključevali okvare pomembnega organa) so se pojavili pri sedmih bolnikih v skupini z rituksimabom
English: Log-rank p value
Slovenian: Vrednost p v testu log rank
English: It is recommended that immunoglobulin levels are determined prior to initiating treatment with Rixathon.
Slovenian: Pred začetkom zdravljenja z zdravilom Rixathon je priporočljivo določiti koncentracije imunoglobulinov.
English: During rituximab maintenance treatment for up to 2 years, leucopenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade 3/4) were reported at a higher incidence when compared to observation.
Slovenian: Incidenca levkopenije in nevtropenije 3. ali 4. stopnje sta bili v skupini, ki je prejemala vzdrževalno zdravljenje z rituksimabom do 2 leti, višja (levkopenija: 5 %, nevtropenija: 10 %) kot v opazovani skupini (levkopenija: 2 %, nevtropenija: 4 %).
English: Patients treated with Rixathon may receive non-live vaccinations.
Slovenian: Bolniki, ki se zdravijo z zdravilom Rixathon, lahko prejmejo mrtva cepiva, vendar je lahko odgovor nanje zmanjšan.
English: What you need to know before you are given Rixathon Do not take Rixathon if
Slovenian: Kaj morate vedeti, preden boste dobili zdravilo Rixathon
English: p < 0.0001
Slovenian: mediana TTP: p < 0,0001
English: The chemotherapy should be given after Rixathon infusion.
Slovenian: Kemoterapijo dajemo po infuziji zdravila Rixathon.
English: Rheumatoid arthritis only
Slovenian: Samo revmatoidni artritis
English: • memory loss, trouble thinking, difficulty walking or sight loss -these may be due to a very rare,
Slovenian: • poslabšanje spomina, motnje mišljenja, težave s hojo ali izguba vida - lahko so posledica zelo redke, resne okužbe možganov, ki je včasih smrtna (imenujemo jo progresivna multifokalna levkoencefalopatija ali PML).
English: Other serious ADRs reported include hepatitis B reactivation and PML (see section 4.4.)
Slovenian: Med drugimi resnimi neželenimi učinki so poročali tudi o reaktivaciji virusa hepatitisa B in o PML
English: The most frequent ADRs following receipt of rituximab in clinical studies were IRRs (refer to Table 2).
Slovenian: Najpogostejši neželeni učinki po prejemu rituksimaba v kliničnih preskušanjih so bile reakcije,
English: Blood and lymphatic system disorders
Slovenian: Bolezni krvi in limfatičnega sistema nevtropenija1
English: • severe skin problems causing blisters that can be life-threatening.
Slovenian: • okvara črevesne stene (predrtje), • hude težave s kožo, ki povzročijo mehurje in so lahko smrtno nevarne.
English: Prophylaxis with adequate hydration and administration of uricostatics starting 48 hours prior to start of therapy is recommended for CLL patients to reduce the risk of tumour lysis syndrome.
Slovenian: Za zmanjšanje tveganja za sindrom lize tumorja je za bolnike s KLL priporočljiva profilaksa s primerno hidracijo in dajanjem urikostatika, ki ga začnemo dajati 48 ur pred pričetkom zdravljenja.
English: B cell levels in human neonates following maternal exposure to rituximab have not been studied in clinical trials.
Slovenian: V kliničnih preskušanjih niso proučevali števila celic B pri novorojenčkih mater, zdravljenih z rituksimabom.
English: It sticks to the surface of a type of white blood cell called “B-Lymphocyte”.
Slovenian: Veže se na površino vrste belih krvnih celic, limfocitov B. Ko se rituksimab veže na površino teh celic, povzroči njihovo smrt.
English: Mean change from baseline: Modified total sharp score Erosion score Joint space narrowing score Proportion of patients with no radiographic change
Slovenian: Ocena zožitve sklepne špranje Delež bolnikov brez radioloških sprememb
English: Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential should use effective contraceptive methods during and for 12 months following treatment with Rixathon.
Slovenian: Zato morajo ženske v rodni dobi med zdravljenjem z zdravilom Rixathon in še 12 mesecev po njem uporabljati učinkovita kontracepcijska sredstva.
English: Bronchitis, sinusitis, gastroenteritis, tinea pedis
Slovenian: Infekcijske in parazitske bolezni okužba zgornjih dihal, okužbe sečil bronhitis, sinuzitis, gastroenteritis, tinea pedis
English: Figure 3:
Slovenian: Preglednica 3.
English: Rixathon is used for the treatment of rheumatoid arthritis.
Slovenian: Zdravilo Rixathon uporabljamo za zdravljenje revmatoidnega artritisa, ki je bolezen sklepov.
English: • indigestion
Slovenian: • omotičnost,
English: • severe vision loss
Slovenian: • hudo poslabšanje vida.
English: ESR
Slovenian: ORR
English: Progression-free survival (PFS) Overall survival
Slovenian: PFS: preživetje brez napredovanja bolezni (Progression-Free Survival)
English: Dizziness may occur following administration of rituximab (see section 4.8).
Slovenian: Po dajanju rituksimaba se lahko pojavi omotica (glejte poglavje 4.8).
English: Rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris
Slovenian: Revmatoidni artritis, granulomatoza s poliangiitisom, mikroskopski poliangiitis in navadni pemfigus
English: Clinical experience in Non-Hodgkin's lymphoma and in chronic lymphocytic leukaemia
Slovenian: Klinične izkušnje pri ne-Hodgkinovem limfomu in kronični limfocitni levkemiji
English: Re-treatment
Slovenian: Zdravilo
English: † Outcome at 24 weeks Significant difference from placebo + MTX at the primary timepoint: ***p ≤ 0.0001
Slovenian: Značilna razlika v primerjavi s placebom ob času primarnega cilja študije: *p < 0,05; **p < 0,001; ***p ≤ 0,0001
English: What Rixathon is used for
Slovenian: Za kaj uporabljamo zdravilo Rixathon
English: Cases of posterior reversible encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy syndrome (RPLS) have been reported.
Slovenian: Poročali so o primerih sindroma posteriorne reverzibilne encefalopatije (PRES, posterior reversible encephalopathy syndrome) oziroma sindroma reverzibilne posteriorne levkoencefalopatije (RPLS,
English: The overall rate of infection was approximately 94 per 100 patient years in rituximab treated patients.
Slovenian: Pri bolnikih, ki so se zdravili z rituksimabom, je bil celokupni delež okužb približno 94 na 100 bolnik let.
English: Corticosteroids will usually be given by injection before the start of Rixathon treatment.
Slovenian: Pred začetkom zdravljenja z zdravilom Rixathon boste ponavadi dobili kortikosteroide v injekciji.
English: • swelling of the hands or ankles
Slovenian: • otekanje rok ali gležnjev.
English: The most frequent adverse reactions considered due to receipt of rituximab IRRs.
Slovenian: Najpogostejši neželeni učinki, za katere so menili, da so nastali zaradi prejetja rituksimaba, so bile reakcije, povezane z infuzijo.
English: Cardiovascular reactions during clinical trials with rituximab monotherapy were reported in 18.8% of patients with the most frequently reported events being hypotension and hypertension.
Slovenian: O kardiovaskularnih neželenih učinkih so med kliničnimi preskušanji rituksimab kot samostojnega zdravila poročali pri 18,8 % bolnikov.
English: You should also tell them about your Rixathon treatment.
Slovenian: Povejte, da se zdravite z zdravilom Rixathon.
English: Vomiting, diarrhoea, abdominal pain, dysphagia, stomatitis, constipation, dyspepsia, anorexia, throat irritation
Slovenian: hipotenzija, rinitis, okorelost, tahikardija, utrujenost, orofaringealna bolečina,
English: % HAQ-DI MCID Mean change in FACIT-T
Slovenian: % bolnikov z MCID v HAQ-DI
English: • coughing or shortness of breath
Slovenian: • kašelj ali kratka sapa,
English: Upon administration of rituximab at a dose of 375 mg/m2 as an intravenous infusion at weekly intervals for 8 doses to 37 patients with NHL, the mean Cmax increased with each successive infusion, spanning from a mean of 243 µg/mL (range, 16 - 582 µg/mL) after the first infusion to 550 µg/mL (range, 171-1,177 µg/mL) after the eighth infusion.
Slovenian: Pri 37 bolnikih z ne-Hodgkinovim limfomom, ki so prejeli 375 mg/m2 rituksimaba z intravensko infuzijo v osmih odmerkih enkrat na teden, se je povprečna Cmax povečala z vsako naslednjo infuzijo, tako da se je iz povprečne vrednosti 243 µg/ml (od 16 do 582 µg/ml) po prvi infuziji povečala na
English: See the Rixathon package leaflet for more information.
Slovenian: Shranjevanje zdravila Rixathon Vsebina pakiranja in dodatne informacije
English: • Signs of PML include: - Confusion, memory loss or problems thinking - Loss of balance or a change in the way you walk or talk - Decreased strength or weakness on one side of your body - Blurred vision or loss of vision.
Slovenian: • Znaki PML vključujejo: - zmedenost, izgubo spomina ali težave pri mišljenju,
English: 500 mg / 50 mL
Slovenian: 100 mg/h na 50 mg/h).
English: The safety of immunisation with live viral vaccines, following rituximab therapy has not been studied for NHL and CLL patients and vaccination with live virus vaccines is not recommended.
Slovenian: Varnosti imunizacije z živimi virusnimi cepivi po zdravljenju z rituksimabom pri bolnikih z NHL in
English: Other medicines and Rixathon
Slovenian: Shranjevanje zdravila Rixathon
English: Other symptoms included flushing, angioedema, bronchospasm, vomiting, nausea, urticaria/rash, fatigue, headache, throat irritation, rhinitis, pruritus, pain, tachycardia, hypertension, hypotension, dyspnoea, dyspepsia, asthenia and features of tumour lysis syndrome.
Slovenian: utrujenost, glavobol, draženje žrela, rinitis, srbenje, bolečina, tahikardija, hipertenzija, hipotenzija, dispneja, dispepsija, astenija in značilnosti sindroma razpada tumorja.
English: You must also do this for 12 months after your last treatment with Rixathon.
Slovenian: Učinkovito kontracepcijsko zaščito morate nadaljevati še 12 mesecev po zadnjem odmerku zdravila Rixathon.
English: Premedication consisting of an anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be given before each administration of Rixathon.
Slovenian: Pred uporabo zdravila Rixathon mora bolnik vedno dobiti premedikacijo, ki obsega antipiretik in antihistaminik, npr. paracetamol in difenhidramin.
English: Anaphylaxis Tumour lysis syndrome, cytokine release syndrome4, serum sickness
Slovenian: Bolezni imunskega sistema z infuzijo povezane reakcije4, angioedem preobčutljivo st anafilaksija sindrom lize tumorja, sindrom sproščanja citokinov4, serumska bolezen z infuzijo povezana akutna reverzibilna trombocitopeni ja4
English: Musculoskeletal and Connective Tissue Disorders
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva mišično-skeletna bolečina
English: Mean pre-therapeutic antibody titres against a panel of antigens (Streptococcus pneumoniae, influenza A, mumps, rubella, varicella) were maintained for at least 6 months after treatment with rituximab.
Slovenian: A, mumps, rdečke, norice) so se ohranili najmanj 6 mesecev po zdravljenju z rituksimabom.
English: Consultation with a Neurologist should be considered as clinically indicated.
Slovenian: Glede na klinično stanje pride v poštev posvet z nevrologom.
English: Rixathon should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3).
Slovenian: Zdravila Rixathon se ne sme dajati bolnikom z aktivno, hudo okužbo (npr. tuberkulozo,
English: For the 60 re-treatments on study, the ORR was 38% (CI95% 26% - 51%; CR 10%, PR 28%) with a projected median TTP for responding patients of 17.8 months (range 5.4-26.6).
Slovenian: Za 60 ponovnih zdravljenj je bil celokupen odgovor na zdravljenje 38 % (95-% interval zaupanja 26-51 %; 10 %
English: This medicine contains 2.3 mmol (or 52.6 mg) sodium per 10 mL vial.
Slovenian: To zdravilo vsebuje 2,3 mmol (ali 52,6 mg) natrija na 10-ml vialo.
English: This medicinal product contains 2.3 mmol (52.6 mg) sodium per 10 mL vial.
Slovenian: To zdravilo vsebuje 2,3 mmol (52,6 mg) natrija na 10-ml vialo.
English: How to store Rixathon
Slovenian: Kako se daje zdravilo Rixathon
English: In a multi-centre, single-arm trial, 37 patients with relapsed or chemoresistant, low grade or follicular B cell NHL received 375 mg/m2 of rituximab as intravenous infusion weekly for eight doses.
Slovenian: V multicentričnem preskušanju brez primerjalne skupine je 37 bolnikov, pri katerih se je nizko maligni ne-Hodgkinov limfom ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo, prejemalo osem odmerkov po 375 mg/m2 rituksimaba v obliki intravenske infuzije enkrat na teden.
English: This medicine contains 11.5 mmol (or 263.2 mg) sodium per 50 mL vial.
Slovenian: To zdravilo vsebuje 11,5 mmol (ali 263,2 mg) natrija na 50-ml vialo.
English: Experience from non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Slovenian: Izkušnje pri ne-Hodgkinovem limfomu in kronični limfocitni levkemiji
English: The recommended dosage of Rixathon for the treatment of pemphigus vulgaris is 1000 mg administered as an IV infusion followed two weeks later by a second 1000 mg IV infusion in combination with a tapering course of glucocorticoids.
Slovenian: Priporočeni odmerek zdravila Rixathon za zdravljenje navadnega pemfigusa je 1.000 mg v intravenski infuziji, ki ji čez dva tedna sledi druga intravenska infuzija 1.000 mg; uporablja se v kombinaciji z glukokortikoidi, katerih odmerke postopoma zmanjšujemo.
English: In a multi-centre, single-arm trial, 58 patients with relapsed or chemoresistant low grade or follicular B cell NHL, who had achieved an objective clinical response to a prior course of rituximab, were re-treated with 375 mg/m2 of rituximab as intravenous infusion weekly for four doses.
Slovenian: V multicentričnem preskušanju brez primerjalne skupine je 58 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo ter so dosegli objektivni klinični odgovor na predhodno zdravljenje z rituksimabom, ponovno prejelo
English: The study showed statistically significant results of rituximab and low-dose prednisone over standarddose prednisone in achieving CRoff ≥ 2 months at month 24 in PV patients (see Table 18).
Slovenian: Študija je pri doseganju CRoff ≥ 2 meseca po 24 mesecih pri bolnikih z navadnim pemfigusom pokazala statistično značilno razliko med shemo rituksimaba in majhnega odmerka prednizona ter shemo s standardnim odmerkom prednizona (glejte preglednico 18).
English: • being sick (vomiting), diarrhoea, pain in the stomach, irritation or ulcers in the throat and mouth, problems swallowing, constipation, indigestion
Slovenian: • bruhanje, driska, bolečine v trebuhu, draženje ali razjede v žrelu in ustih, težave s požiranjem,
English: Patients in both arms received 1,000 mg of pulse intravenous methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day).
Slovenian: Bolniki v obeh terapevtskih skupinah so prejemali 1.000 mg metilprednizolona (ali drugega glukokortikoida v enakovrednem odmerku) na dan pulzno intravensko (i.v.)
English: Rixathon 500 mg concentrate for solution for infusion rituximab
Slovenian: Rixathon 500 mg koncentrat za raztopino za infundiranje Rituximabum (rituksimab)
English: Regular full blood counts, including neutrophil and platelet counts, should be performed during Rixathon therapy.
Slovenian: Med zdravljenjem z zdravilom Rixathon je treba redno kontrolirati celotno krvno sliko, vključno s številom nevtrofilcev in trombocitov.
English: Bronchospasm4, respiratory disease, chest pain, dyspnoea, increased cough,
Slovenian: Bolezni dihal, prsnega koša in mediastinalne ga prostora bronhospaze m4, bolezen dihal,
English: • Fever or persistent cough
Slovenian: • zvišana telesna temperatura ali trdovraten kašelj,
English: Rixathon 100 mg concentrate for solution for infusion rituximab
Slovenian: Rixathon 100 mg koncentrat za raztopino za infundiranje Rituximabum (rituksimab)